Advertisement SCT hires new CFO - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Stem Cell Therapeutics (SCT) has appointed Michael Cook as chief financial officer (CFO) of the company.

Cook has over 15 years of business experience and has expertise in corporate finance, private equity and corporate management, and brings a combination of skills and experience to the team at SCT.

SCT CEO Alan Moore said that they were fortunate to have Cook in the key role as CFO and they welcome him to the management team.

SCT is a biotechnology company focused on the development and commercialisation of drug-based therapies to treat central nervous system diseases.

SCT is engaged in the development of therapies that utilise drugs to stimulate a patient’s own resident stem cells.